CXCL9 and ovarian cancer: Treatment of mice with EZH2 inhibitor, 3-Deazaneplanocin A (DZNep) or DAC reversed this repression of CXCL9 and CXCL10 and improved responses to CD8+ T cell therapy in an ovarian cancer model [109].